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CHAPTER 1. INTRODUCTION
The 2006 Institute of Medicine (IOM) report “From Cancer Patient to
Cancer Survivor: Lost in Transition” recommends “health care providers should
use systematically developed evidence-based clinical practice guidelines,
assessment tools, and screening instruments to help identify and manage late
effects of cancer and its treatment.” Without these guidelines, the practices of
health care providers will vary widely, leading to inefficiencies in the delivery of
care. The report emphasizes the need for evaluating the impact of guidelines in
the context of cancer care.
Spending on medical treatment for cancer in the United States accounts
for nearly 103 billion dollars annually, with the administering of chemotherapy
agents driving the cost of treating advanced stages of the disease.
Understanding the extent to which chemotherapy use in practice is consistent
with these guidelines as well as the factors associated with inappropriate
chemotherapy use has rarely been studied among large populations, mainly
because performance status (PS), a key clinical component in assessing
chemotherapy

appropriateness,

is

typically

missing

from

claims-based

databases. The purpose of PS is to quantify the general well-being of a cancer
patient. It is used to determine whether patients can receive chemotherapy,
whether dose adjustment is necessary, as a measure for the required intensity of
palliative care, and as a quality of life measure in randomized controlled trials.
The goal of this research is to quantify the non-guideline concordant use
of chemotherapy within an insured population diagnosed with lung cancer with
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documented PS, and to evaluate the factors associated with under- and over-use
of chemotherapy within this cohort. By combining data from medical records with
those available via an automated tumor registry, medical claims, and Census
data, I was able to consider the patients’ clinical and socio-demographic
characteristics, as well as characteristics of the neighborhoods in which the
patients reside.
A key factor in evaluating appropriateness of chemotherapy in lung cancer
is the “performance status” (PS) of the patient. PS is a subjective measure used
by clinicians to assess functional capacity and the likelihood of adverse events,
quality of life, and survival after treatment. Measures of PS are currently not
available through automated claims data. This void acts as an impediment in
comparative effectiveness research. In chapter 2, I develop a tool to estimate PS
using claims-based measures. I used chart abstracted PS (from the medical
record) and linked it to automated medical and pharmaceutical claims and tumor
registry data.
In chapter 3, I describe the sample of chemotherapy users and nonusers
and

examine

the

factors

associated

with

underuse

and

overuse

of

chemotherapy. Patients with good PS, for whom chemotherapy treatment is
recommended, who did not receive chemotherapy are classified as under-users.
Patients with poor PS, who received chemotherapy despite guideline
recommendations against its use, are classified as over-users. I use logistic
regression to estimate two models. The first model tests non-receipt of
chemotherapy among patients with good PS and the second considers the
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receipt of chemotherapy among patients with poor PS. In both models, I consider
patient-level characteristics including demographic, clinical, socioeconomic, and
health care access measures.
In the final chapter, I focus on the outcomes associated with the choice of
adherence to guidelines. Specifically, I am evaluating the relationship of overand under-use with survival. To account for the endogeneity of chemotherapy
receipt in estimating outcomes I use a two-stage residual inclusion (2SRI) model.
The first stage equation represents a logistic regression for factors associated
with receipt of chemotherapy (same equation from chapter 3). For survival, the
second stage equation is the Cox proportional hazard model.
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CHAPTER 2. USING CLAIMS-BASED MEASURES TO PREDICT
PERFORMANCE STATUS IN PATIENTS WITH LUNG CANCER

Performance status (PS) is a good prognostic factor in lung cancer and is
used

to

assess

chemotherapy

appropriateness.

Researchers

studying

chemotherapy use are often hindered by the unavailability of PS in automated
data sources. To my knowledge, no attempts have been made to estimate PS
using claims-based measures. The current study explored the ability to estimate
PS using routinely available measures.
A cohort of insured patients aged ≥ 50 years who were diagnosed with
American Joint Committee on Cancer stage II through IV lung cancer between
2000 and 2007 was identified via a tumor registry (n = 552). PS was abstracted
from medical records. Automated medical and pharmaceutical claims from the
year preceding diagnosis were linked to tumor registry data. A logistic regression
model was fit to estimate good versus poor PS in a random half of the sample. C
statistics, sensitivity, specificity, and R2 were used to compare the predictive
ability of models that included demographic factors, comorbidity measures, and
claims-based utilization variables. Model fit was evaluated in the other half of the
sample.
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2.1 Introduction
Since 1997, evidence-based guidelines have recommended the use of
chemotherapy for medically fit patients with lung cancer to improve survival,
symptoms, and quality of life (1997;2010c;D. G. Pfister et al. 2004;2010b).
Despite these recommendations, numerous studies (T. J. Smith et al. 1995;P. B.
Bach et al. 1999;C. C. Earle et al. 2000;A. L. Potosky et al. 2004) have illustrated
variability in the receipt of chemotherapy among patients with lung cancer.
Nevertheless, the ability to determine the appropriateness of observed treatment
variability has been greatly hindered by voids in the clinical information
necessary to judge appropriateness.
One key factor in evaluating the appropriateness of chemotherapy is the
patient’s performance status (PS) (1997;2010b;2010c;D. G. Pfister et al. 2004).
PS is a subjective composite measure used by clinicians to assess current
functional capacity and the likelihood of adverse events, quality of life, and
survival after treatment. Measures of PS are currently not available through
automated medical claims, tumor registries, or other observational data
commonly used to study cancer treatment and its associated outcomes. Thus,
the use of such data to address questions regarding chemotherapy has been
relatively limited and when undertaken, the inability to consider PS is a noted
limitation (A. L. Potosky et al. 2004;B. E. Hillner et al. 1998;C. J. Bradley et al.
2008). The systematic lack of information regarding PS similarly impedes the
ability of researchers to use existing automated, observational data for
comparative effectiveness research.
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This chapter asks two questions. First, how often are measures of a
patient’s PS documented in his or her detailed medical record? Second, is it
possible to accurately estimate a patient’s PS using routinely available tumor
registry and claims- based measures on that patient’s demographics,
comorbidities, and prior healthcare utilization? By using a cohort of lung cancer
patients diagnosed between 2000 and 2007, the feasibility of using medical
record documentation to obtain PS measures was described overall and by
patient characteristics. Medical record-documented PS information was then
combined with information routinely available in an automated tumor registry as
well as medical and pharmaceutical claims data to evaluate the feasibility of
estimating PS among lung cancer patients using information routinely available in
observational data sources. To my knowledge, this has not previously been
attempted among patients with lung or other cancers.

2.2 Materials and Methods
Study Population and Setting
Study patients were those receiving care from a 900-physician member,
multispecialty, salaried medical group practice in southeast Michigan. Data
available from the medical group’s tumor registry were used to identify all
patients aged ≥ 50 years who were diagnosed with lung cancer between January
1, 2000 and December 31, 2007. The medical group, which provides care under
both fee-for-service and capitated arrangements, staffs 27 primary care clinics
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throughout Detroit and the surrounding metropolitan area. Patients eligible for
study inclusion were those continuously enrolled in an affiliated health plan
(i.e., health maintenance organization) for the 1-year period preceding their date
of lung cancer diagnosis. Patients for whom no stage of disease was available at
the time of diagnosis or for whom the stage at diagnosis was 0 to I were
excluded because chemotherapy was not indicated for patients with stage 0 or I
disease during this time period (W. J. Scott et al. 2007). The medical group’s
Institutional Review Board approved all aspects of the study protocol.

PS Measurement
The 2 most commonly used PS systems are the Eastern Cooperative
Oncology Group (ECOG) scale and the Karnofsky performance scale (KPS) (S.
P. Blagden et al. 2003). Although the 2 scales are not identical, they are
generally believed to capture the
same conceptual domain and conversions are possible between them (Table 1)
(G. Buccheri et al. 1996). Two trained chart abstractors reviewed inpatient and
outpatient nursing and physician notes available within the patient’s electronic
medical record from 2 months before diagnosis until the first notation of death,
disenrollment, initiation of chemotherapy, or 6 months after diagnosis. If
available, abstractors documented specific numeric PS and scale (i.e., ECOG or
KPS). Patients were assigned a good PS if they had an ECOG score of 0 or 1 or
a KPS score of 80 to 100. A poor PS was assigned to patients with an ECOG
score of 2 to 5 or a
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KPS score of 0 to 70. This was done to be consistent with standards in practice
regarding recommendations for chemotherapy use among lung cancer patients
during the study period (1997;2010b;2010c;D. G. Pfister et al. 2004), as well as
with existing research applications (R. C. Lilenbaum et al. 2008), With the
issuance of the 2009 American Society of Clinical Oncology (ASCO) guidelines,
the standard for chemotherapy use changed to include the consideration of use
in those patients with an ECOG score of 2 or a KPS score of 60 to 70. Thus, we
also presented alternative results for which those patients with these scores were
realigned to a good PS.
If no numeric score was documented, abstractors collected medical record
documentation of good or poor PS. If no reference to PS was documented in the
medical record, notes regarding the patient’s functionality (e.g., references to
shortness of breath, use of a wheelchair or other personal mobility devices, labor
force participation, exercising habits, activities of daily living, or other references
to mobility) were recorded and used to estimate PS. Inter-rater reliability between
the 2 abstractors was assessed on a random subset of 40 observations. The
resulting Cohen κ was 0.88. Among the inter-rater reliability subset (N = 40), in
each incident in which the abstracted PS did not match between the 2
abstractors (3 cases), 1 abstractor indicated good or poor whereas the other
selected unknown PS. For the final analytical database, these differences were
reconciled by choosing good/poor over unknown.

9
Automated Tumor Registry and Claims Data
Automated tumor registry and claims data were used to obtain patient
demographic characteristics, cancer stage, and diagnoses for each patient.
Demographic measures included age, gender, and race. The age of the patient
(in years) was recorded as of the date of lung cancer diagnosis. Clinical variables
examined included stage of disease at the time of diagnosis and the Charlson
comorbidity index (M. E. Charlson et al. 1987). Cancer stage was reported using
the American Joint Committee on Cancer (AJCC) stages II through IV. A
dichotomous variable was created to control for AJCC stage IV patients in the
regression analysis. The Deyo adaptation of the Charlson comorbidity index and
each of its component diagnostic subgroups were constructed using inpatient
and outpatient diagnostic information available in the 12-month period preceding
diagnosis (R. A. Deyo et al. 1992). In addition, claims data provided information
regarding prescription drugs dispensed and medical care use within the 12month period preceding lung cancer diagnosis.
Medical care use measures included those reflective of inpatient stays in a
short-stay hospital or skilled nursing facility (SNF); ambulatory care visits;
emergency department visits; and use of home health services, same-day
surgery, and durable medical equipment (DME). For each person, inpatient use
measures included the total number of distinct inpatient stays, the total number of
inpatient days, and the average length of an inpatient stay for those with a non-0
number of stays. The number of outpatient visits was recorded, and in the
regression analysis a dichotomous variable was created to control for patients
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with non-0 outpatient visits. Similar dichotomous variables were constructed to
reflect any drug dispensing and any DME use. The emergency department,
home health, and same-day surgery use variables measured the counts of visits
incurred. We also evaluated the use of a count of the distinct number of
medications dispensed during the baseline year, as recommended by
Schneeweiss et al (S. Schneeweiss et al. 2001). For this measure, medications
whose first 8 digits of the American Hospital Formulary Services code were equal
were considered to be the same drug (2010a).

Statistical Analysis
Among the cohort of lung cancer patients, we reported the frequency of
documented PS in medical records and described the different ways PS was
recorded. Systematic differences between patients for whom PS was recorded
and patients for whom it was not recorded were examined using 2-sample
Student t tests (or Wilcoxon rank sum tests) and chi-square tests, depending on
the nature of the characteristic. Similar analyses were conducted to compare
unadjusted differences in patient characteristics by good PS versus poor PS.
Multivariable logistical regression models were fit to evaluate the feasibility of
using routinely available observational data to predict good versus poor PS.
Three separate models were estimated, reflective of 3 different levels of the
comprehensiveness of observational data routinely available. The first regression
model included only those variables typically available via tumor registries
(demographics and stage of disease). The second model included those same
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variables plus measures of medical care use and diagnoses available in medical
claims data. The third model added measures of prescription drug use routinely
available via pharmaceutical claims.
For each model, a split-sample cross validation was used to check for
model overfitting. C statistics, sensitivity, specificity, and R2 were used to assess
and compare the predictive ability of the different models. Initially, all variables
were considered for inclusion. However, the final model in each of the 3
categories was fit using the stepwise elimination method. Pairwise interactions
were tested but were not found to enhance model prediction. Likewise, we
evaluated the need to account for the non-independence of patients seen by the
same physician, but because the intra-class correlation coefficient (ICC) was
negligible (ICC = 0.01), we elected not to do so because not doing so enabled us
access to additional assessment of model fit. The final models were estimated on
the full sample and bootstrapping was used to replicate each final model 1000
times to create 95% confidence intervals around the c and R2 statistics (B. Efron,
G. Gong 83 A.D.).
To examine model discrimination, patients were ranked by their predicted
probability of good PS based on each model. Patients were then divided into
deciles based on increasing predicted probability of good PS and actual good PS
rates were reported among patients in all deciles to suggest how well models
separated patients with good PS from those with poor PS (S. Lemeshow, D. W.
Hosmer, Jr. 1982). SAS statistical software (version 9.1.3; SAS Institute Inc,
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Cary, NC) was used for all analyses. P < .05 was considered to be statistically
significant.
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Table 1. The Eastern Cooperative Oncology Group (ECOG) Performance Status
Score (PS) and its Karnofsky PS Equivalent
ECOG
Grade
0
1

2

3
4
5

Karnofsky
Description
Fully active, able to carry on all pre-disease performance
without restriction
Restricted in physically strenuous activity but ambulatory and
able to carry out work of a light or sedentary nature (e.g., light
house work, office work)
Ambulatory and capable of all self care but unable to carry
out any work activities. Up and about more than 50% of
waking hours
Capable of only limited self care, confined to bed or chair
more than 50% of waking hours
Completely disabled. Cannot carry on any self care; confined
to bed or chair
Dead

100
80-90

60-70

40-50
20-30
0-10
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2.3 Results
Cohort Characteristics
A total of 552 patients met the criteria for study eligibility. The mean age of
the patients at diagnosis was 67.4 years (standard deviation [SD], 9.1 years). Of
the patients eligible for the study, 42% were female, whereas the racial
distribution was 69% white and 31% black. The AJCC staging distribution was as
follows: 9% of patients were diagnosed with stage II disease, 20% with stage IIIA
disease, 19% with stage IIIB disease, and 52% with stage IV disease. The
average Charlson comorbidity index across the eligible sample was 2.8 (SD,
3.4), whereas the average number of distinct prescription drugs used in the year
before diagnosis was 9.3 (SD, 7.1).
The average number of inpatient days in the year before diagnosis for the
cohort (including those with no inpatient stays) was 2.9 days (SD, 7.5 days),
whereas the average number of inpatient stays was 0.5 (SD, 0.8), resulting in an
average inpatient length of stay of 5.0 days (SD, 5.2 days). The average number
of outpatient visits was 5.7 (SD, 8.5) and the average number of emergency
department visits was 0.6 (SD, 1.1) for the same time period. Across the studyeligible sample, 28% recorded any home health use, 3% had same-day surgery,
12% incurred a DME dispensing, and 4% incurred a stay in a rehabilitation facility
or SNF. None incurred a hospice stay in the period before the lung cancer
diagnosis.
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Medical Record Documentation of PS
Of the 552 study eligible patients, PS was recorded in the medical record
for 261 cases (47%). Among these, a numeric score was documented in 248
cases (95%), with the ECOG scale most often used (74%). For the remaining
13 patients, although a numeric score was not documented, explicit
documentation was found of either good or poor PS.
Among the 291 (53%) patients for whom PS was not recorded, there were
181 for whom there was a sufficient verbal description of the patient’s functioning
in either the physician’s notes, nurse’s notes, or a combination of both to enable
a determination of either a good or poor PS score. Thus, overall there were 442
patients (80%) for whom PS was determinable in their medical record.
Differences in patient characteristics by PS documentation level are
reported in Table 2. The first 2 columns compare those patients for whom
medical record documentation could be used to determine PS (known PS) with
those for whom medical record documentation was insufficient to determine PS
(unknown PS). As shown, patients with unknown PS (n = 110) did not differ
significantly from those with a known PS (n = 442) with regard to demographic or
clinical characteristics or measures of medical care use.
Among patients with a known PS, the third and fourth columns of Table 2
compare patient characteristics between those who had a documented PS
(either numeric or verbal) with those for whom a PS was extrapolated based on
notes in the medical record. No significant differences were observed for most
measures. However, there were significant differences by gender, diagnosis of
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atherosclerotic cardiovascular disease, and the average number of inpatient
days.

Patient Factors Associated With PS
Among the 442 patients for whom PS was known, 290 patients (66%) had
a good PS using the pre-2009 definition of good and 152 (34%) had a poor PS.
This changed to 76% with a good PS and 24% with a poor PS when those with a
documented numeric PS of 2 were considered to have good PS, as would be
consistent with that in the 2009 ASCO guidelines for the use of chemotherapy.
The unadjusted differences in patient characteristics by PS are illustrated in
Table 3. Compared with patients with good PS, patients with poor PS were
significantly older (69.7 years vs. 66.4 years) and more likely to be male (66% vs.
54%), have stage IV disease (64% vs. 44%), and have a significantly higher
Charlson comorbidity index (3.6 vs. 2.4). Consistent with the latter finding,
patients with poor PS were significantly more likely to have been diagnosed with
several of the individual components of the Charlson comorbidity index when
compared with those with good PS. Patients with poor PS also incurred
significantly more inpatient days (5.5 days vs. 1.7 days) as well as longer lengths
of stay (6.8 days vs. 5.4 days) in the year before diagnosis, and were more likely
to have incurred any outpatient visit, home health use, or DME use in the year
before diagnosis. Also of note is that patients with poor PS were significantly less
likely to have undergone chemotherapy in the year after diagnosis (42% vs. 82%)
(data not shown). Similar differences between the groups were found when those
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with a PS of 2 were realigned with the good PS group, with 2 exceptions:
statistically significant differences in gender and the prevalence of peripheral
vascular disease no longer existed.

Predicting Performance Status
Results from the logistical regression models predicting good versus poor
PS defined the 2 ways are presented in Table 4. Results are presented for
models fit on the full sample and include only significant (P < .05) variables per
the stepwise regression. In the model that included only tumor registry variables,
only age at diagnosis and AJCC stage were selected (Model 1). Diagnosis of
chronic pulmonary disease, the number of inpatient stays, any outpatient visits,
and the number of emergency department admissions were all added when
information from medical claims data were considered (Model 2). One more
variable, the number of distinct prescription drugs, was added when information
from pharmaceutical claims data was considered (Model 3).
Statistical performance improved with the inclusion of additional
explanatory variables (Table 4). Cross-validated C and R2 values were never
more than 0.01 smaller than fitted values. By using a predictive threshold of 0.50,
a high sensitivity (0.88 or 0.94, depending on how good PS was defined) was
obtained with the best model (Model 3), but with moderate specificity (0.45 or
0.32). Increasing the predictive threshold to 0.70 continued to yield relatively high
sensitivity (0.64 or 0.83) and more moderate specificity (0.69 or 0.55), regardless
of how good PS is defined.
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Table 5 shows the actual and predicted good PS rates for patients within
each of the 10 deciles. As measured by the Hosmer-Lemeshow chi-square
statistic (S. Lemeshow, D. W. Hosmer, Jr. 1982), all models had good calibration,
in which actual and predicted rates within each of the 10 deciles were not
significantly different (P = .69, P = .32, and P = .13 for Models 1-3, respectively)
when a PS of 2 was defined as poor and likewise not significantly different (P =
.92, P = .63, and P = .98 for Models 1-3, respectively) when a PS of 2 was
defined as good. Model discrimination was also improved with the inclusion of
more explanatory variables.
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Table 2. Sample Characteristics, and Prescription Drug and Medical Care
Utilization in the Year Prior to Diagnosis of Lung Cancer, by Performance Status
(PS) documentation level, (n = 552)
Characteristic

Demographic Characteristics
Average diagnosis age (SD)
Gender (%)
Female
Male
Race (%)
Asian
Black
White
Clinical Characteristics
AJCC stage (%)
II
IIIA
IIIB
IV
Average Charlson score (SD)
Atherosclerotic cardiovascular disease (%)
Congestive heart failure (%)
Ischemic heart disease (%)
Peripheral vascular disease (%)
Dementia (%)
Pelvic ulcer disease (%)
Rheumatologic disease (%)
Chronic pulmonary disease (%)
Liver disease (%)
Diabetes (%)
Diabetes with complications (%)
Paralysis (%)
AIDS (%)
Cancer (%)
Cancer with metastasis (%)
Renal disease (%)
Aneurysm (%)
Gangrene (%)
Prescription Drug Utilization
Average no. of dispensings (SD)
Pct with ≥ 1 dispensing
Medical Care Utilization
Average no. IP days (SD)
Average no. IP stays (SD)
Average length of IP stays (SD)
Average no. of OP visits (SD)
Pct with ≥ 1 OP visit
Average ≥ 1 ED visit (SD)
Pct with ≥ 1 home health claim
Pct with ≥ 1 ambulatory surgery claim
Pct with ≥ 1 rehabilitation/SNF claim
3
Pct with ≥ 1 DME claim

Unknown
PS
(n =110)

Known PS
(n = 442)

Documented
PS
(n = 261)

Extrapolated
PS
(n = 181)

66.9 (9.9)

67.5 (8.8)

68.0 (8.6)

66.9 (9.2)

45
55

42
58

38
62

48
52

0
31
69

1
30
69

1
28
71

0
34
66

4
17
24
54
2.7 (3.6)
15.4
16.4
8.2
11.8
0.9
2.7
5.4
32.7
2.7
19.1
4.6
1.8
1.8
24.6
5.4
6.4
6.4
0.9

11
20
18
51
2.8 (3.3)
21.3
17.4
9.3
13.4
1.1
3.6
6.3
41.4
1.4
28.3
4.5
0.9
1.1
29.9
7.5
5.7
6.3
0.7

10
19
17
54
2.9 (3.5)
*
24.5
18.4
10.3
14.2
1.5
3.8
6.1
41.4
0.8
29.9
4.2
1.1
1.1
28.0
8.0
6.1
7.3
0.8

11
22
20
47
2.7 (3.1)
*
16.6
16.0
7.7
12.2
0.6
3.3
6.6
41.4
2.2
26.0
5.0
0.6
1.1
32.6
6.6
5.0
5.0
0.6

8.7 (7.0)
85

9.4 (7.1)
89

9.5 (7.1)
91

9.3 (7.2)
86

2.7 (6.8)
0.4 (0.7)
5.8 (5.2)
5.9 (8.3)
75
0.7 (1.0)
25.4
2.7
4.6
10.9

3.0 (7.7)
0.5 (0.8)
6.1 (5.2)
5.6 (8.6)
76
0.6 (1.1)
29.0
3.2
3.8
12.0

2.4 (5.1)
*
0.4 (0.7)
6.0 (5.3)
5.7 (9.1)
77
0.7 (1.2)
31.4
3.4
5.0
13.4

*

*

*

3.9(10.4)
*
0.6 (0.8)
6.1 (5.0)
5.5 (7.8)
76
0.5 (1.0)
25.4
2.8
2.2
9.9

*
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1

Among all patients (including those with no inpatient stays).
No. of inpatient days divided by no. of inpatient stays – among patients with at least one
inpatient stay.
3
DME included claims for portable oxygen, walkers, canes, wheelchairs, and hospital beds.
*
Significant difference at 5% level.
Abbreviations: standard deviation (SD); percent (Pct); number (no.); American Joint Committee
on Cancer (AJCC); inpatient (IP); outpatient (OP); emergency department (ED); skilled nursing
facility (SNF); durable medical equipment (DME).

2
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Table 3. Among Patients with Known Performance Status (PS), Sample
Characteristics, and Prescription Drug and Medical Care Utilization in the Year
Prior to Diagnosis of Lung Cancer, by PS (n=442)
Pre 20091

Characteristic

Good PS
( n = 290 )
Demographic Characteristics
Average diagnosis age (SD)
Gender (%)
Female
Male
Race (%)
Asian
Black
White
Clinical Characteristics
AJCC Stage (%)
II
IIIA
IIIB
IV
Average Charlson score (SD)
Atherosclerotic cardiovascular disease (%)
Congestive heart failure (%)
Ischemic heart disease (%)
Peripheral vascular disease (%)
Dementia (%)
Pelvic ulcer disease (%)
Rheumatologic disease (%)
Chronic pulmonary disease (%)
Liver disease (%)
Cancer (%)
Cancer with metastasis (%)
Diabetes (%)
Diabetes with complications (%)
Paralysis (%)
AIDS (%)
Renal disease (%)
Aneurysm (%)
Gangrene (%)
Prescription Drug Utilization
Average no. of dispensings (SD)
Pct with ≥ 1 dispensing
Medical Care Utilization
Average no. IP days (SD)3
Average no. IP stays (SD)
Average length of IP stays (SD)4
Average no. of OP visits (SD)

Poor PS
( n = 152 )

Post 20092
Good PS
( n = 336)

Poor PS
( n = 106 )

66.4 (9.1)*

69.7 (7.9)*

66.8 (8.9)*

70.0 (8.1)*

46*
54

34*
66

43
57

38
62

1
28
71

1
34
65

1
28
71

0
38
62

13
24
19
44*
2.4 (3.0)*
19.3
12.1*
6.6*
10.3*
0.0*
2.1*
5.9
34.5*
1.0
28.3
6.6
26.2
3.8
0.3
1.0
3.8*
5.2
0.3

7
13
16
64*
3.6 (3.8)*
25.0
27.6*
14.5*
19.1*
3.3*
6.6*
7.2
54.6*
2.0
32.9
9.2
32.2
5.9
2.0
1.3
9.2*
8.6
1.3

11
23
19
47*
2.5 (3.1) *
19.9
14.3*
7.7*
12.2
0.0*
2.4*
6.3
35.4*
1.0
27.7
6.8
28.0
3.9
0.3
0.9
3.9*
6.2
0.3

9
11
17
63*
3.9 (3.9) *
25.5
27.4*
14.2*
17.0
4.7*
7.6*
6.6
60.4*
3.0
36.8
9.4
29.2
6.6
2.8
1.9
11.3*
6.6
1.9

9.0 (7.1)
87

10.3 (7.2)
93

9.1 (7.1)
88

10.5 (7.3)
92

1.7 (3.9)*
0.3 (0.6)
5.4 (4.8)
6.0 (8.5)

5.5 (11.7)*
0.8 (1.0)
6.8 (5.5)
4.9 (8.7)

1.8 (4.1) *
0.3 (0.6)
5.7 (5.1)
6.0 (8.6)

6.8 (13.3) *
0.9 (1.1)
6.7 (5.2)
4.5 (8.6)
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Pct with ≥ 1 OP visit
Average ≥ 1 ED visit (SD)
Pct with ≥ 1 home health claim
Pct with ≥ 1 ambulatory surgery claim
Pct with ≥ 1 rehabilitation/SNF claim
Pct with ≥ 1 DME claim5

1

82*
0.5 (0.9)*
23.1*
3.8
3.1
6.9*

66*
0.8 (1.3)*
40.1*
2.0
5.3
21.7*

81*
0.5 (1.0)*
24.7*
3.6
3.3
8.0*

63*
0.9 (1.3) *
42.4*
1.9
5.7
24.5*

Pre 2009: Good PS = ECOG: 0 – 1; KPS: 80 – 100; Poor PS = ECOG: 2 – 5; KPS: 0 – 70.
Post 2009: Good PS = ECOG: 0 – 2; KPS: 60 – 100; Poor PS = ECOG: 3 – 5; KPS: 0 – 50.
3
Among all patients (including those with no inpatient stays).
4
No. of inpatient days divided by no. of inpatient stays – among patients with at least one
inpatient stay.
5
DME included claims for portable oxygen, walkers, canes, wheelchairs, and hospital beds.
*
Significant difference at 5% level.
Abbreviations: standard deviation (SD); percent (Pct); number (no.); American Joint Committee
on Cancer (AJCC); inpatient (IP); outpatient (OP); emergency department (ED); skilled nursing
facility (SNF); durable medical equipment (DME).
2
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Table 4. Estimated Logistic Regression Parameters (β) and Standard Errors (SE)
and Measures of Model Performance for Alternative Models of Performance
Status Predictors
PS (Pre 2009): Good/Poor1
Variable
Intercept
Age in years at diagnosis
AJCC Stage IV
Chronic pulmonary disease
Number of Inpatient Stays
Any number of outpatient
visits
Number of ED visits
Any number of DME claim
Any prescription drug
dispensing

Model 1
β
SE
3.97 0.85***
-0.04 0.01**
-0.84 0.21***

Model 2
β
SE
3.65 0.94***
-0.04 0.01**
-0.81 0.23**
-0.67 0.24**
-0.58 0.16**
1.05 0.26***
-0.22
-0.80

0.10*
0.35*

Model 3
β
SE
4.55 1.03***
-0.04 0.01**
-0.84 0.23**
-0.63 0.24**
-0.60 0.16**
1.19 0.27***
-0.22
-0.81
-1.08

0.10*
0.36*
0.43*

Model Performance
C statistic (95% CI)
R2 (95% CI)

0.66 (0.61, 0.71)
0.07 (0.03, 0.11)

0.75 (0.71, 0.81)
0.19 (0.13, 0.26)

0.76 (0.72, 0.81)
0.20 (0.15, 0.28)

Predictive Threshold = 0.50
Sensitivity (95% CI)
Specificity (95% CI)
False positive (95% CI)
False negative (95% CI)

0.88 (0.78, 1.00)
0.20 (0.00, 0.40)
0.32 (0.28, 0.37)
0.54 (0.29, 0.87)

0.90 (0.84, 0.94)
0.43 (0.31, 0.55)
0.25 (0.21, 0.29)
0.31 (0.24, 0.40)

0.88 (0.84, 0.93)
0.45 (0.34, 0.56)
0.25 (0.20, 0.29)
0.34 (0.25, 0.40)

Predictive Threshold = 0.60
Sensitivity (95% CI)
Specificity (95% CI)
False positive (95% CI)
False negative (95% CI)

0.72 (0.61, 0.83)
0.43 (0.27, 0.65)
0.29 (0.23, 0.33)
0.55 (0.46, 0.62)

0.79 (0.72, 0.87)
0.53 (0.45, 0.66)
0.24 (0.18, 0.27)
0.43 (0.34, 0.49)

0.79 (0.72, 0.87)
0.55 (0.47, 0.67)
0.23 (0.18, 0.26)
0.42 (0.34, 0.48)

Predictive Threshold = 0.70
Sensitivity (95% CI)
Specificity (95% CI)
False positive (95% CI)
False negative (95% CI)

0.49 (0.33, 0.65)
0.75 (0.60, 0.88)
0.21 (0.16, 0.26)
0.56 (0.51, 0.62)

0.61 (0.52, 0.74)
0.69 (0.60, 0.79)
0.21 (0.16, 0.25)
0.52 (0.44, 0.57)

0.64 (0.53, 0.75)
0.69 (0.61, 0.79)
0.20 (0.15, 0.25)
0.50 (0.43, 0.56)
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PS (Post 2009): Good/Poor2
Variable
Intercept
Age in years at diagnosis
AJCC Stage IV
Chronic pulmonary disease
Number of Inpatient Stays
Any number of outpatient
visits
Number of ED visits
Any number of DME claim
Any prescription drug
dispensing

Model 1
β
SE
4.39 0.94***
-0.04 0.01***
-0.64 0.23***

Model 2
β
SE
4.25 1.08***
-0.04 0.02**
-0.55 0.26**
-0.88 0.27***
-0.80 0.17***
1.08 0.29***
-0.25
-0.60

0.11**
0.36*

Model 3
β
SE
5.08 1.18***
-0.04 0.02**
-0.57 0.26**
-0.83 0.27***
-0.81 0.17***
1.20 0.30***
-0.25
-0.61
-0.98

0.11**
0.36*
0.50*

Model Performance
C statistic (95% CI)
R2 (95% CI)

0.64 (0.58, 0.70)
0.04 (0.01, 0.08)

0.78 (0.74, 0.84)
0.19 (0.13, 0.28)

0.78 (0.74, 0.85)
0.20 (0.14, 0.28)

Predictive Threshold = 0.50
Sensitivity (95% CI)
Specificity (95% CI)
False positive (95% CI)
False negative (95% CI)

1.00 (0.98, 1.00)
0.00 (0.00, 0.01)
0.24 (0.20, 0.28)
1.00 (0.98, 1.00)

0.94 (0.91, 0.97)
0.28 (0.19, 0.47)
0.19 (0.15, 0.22)
0.40 (0.23, 0.48)

0.94 (0.91, 0.97)
0.32 (0.21, 0.50)
0.19 (0.14, 0.22)
0.38 (0.21, 0.46)

Predictive Threshold = 0.60
Sensitivity (95% CI)
Specificity (95% CI)
False positive (95% CI)
False negative (95% CI)

0.96 (0.87, 1.00)
0.06 (0.00, 0.27)
0.24 (0.20, 0.27)
0.71 (0.37, 1.00)

0.90 (0.86, 0.94)
0.42 (0.29, 0.59)
0.17 (0.13, 0.20)
0.42 (0.32, 0.52)

0.90 (0.86, 0.94)
0.45 (0.32, 0.60)
0.16 (0.12, 0.20)
0.42 (0.32, 0.51)

Predictive Threshold = 0.70
Sensitivity (95% CI)
Specificity (95% CI)
False positive (95% CI)
False negative (95% CI)

0.76 (0.62, 0.91)
0.37 (0.13, 0.63)
0.21 (0.16, 0.24)
0.67 (0.55, 0.78)

0.83 (0.78, 0.99)
0.56 (0.22, 0.72)
0.14 (0.11, 0.21)
0.49 (0.28, 0.58)

0.83 (0.76, 0.88)
0.55 (0.46, 0.70)
0.15 (0.10, 0.17)
0.50 (0.41, 0.57)

Model 1: Significant (P<0.05) performance status predictors from tumor registries (age at
diagnosis and AJCC stage). Model 2: Significant performance status predictors from medical
claims (age at diagnosis, diagnosis of COPD, inpatient stays, any outpatient visits, and
emergency department visit). Model 3: Significant performance status predictors from tumor
registries, medical claims, and pharmacy claims (age at diagnosis, AJCC stage, diagnosis of
COPD, inpatient stays, any outpatient visits, emergency department visit, and any prescriptions).
*
**
***
P<0.05; P<0.01; P<0.0001.
Abbreviations: American Joint Committee on Cancer (AJCC); emergency department (ED);
durable medical equipment (DME); chronic pulmonary disease (COPD).
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Table 5. Number of Patients with Observed (Predicted) Good Performance
Status (PS) by Model and Model Determined Decile
Rank
Deciles
1
2
3
4
5
6
7
8
9
10
P value
Rank
Deciles
1
2
3
4
5
6
7
8
9
10
P value

1

Number with Observed (Predicted) Good PS (Pre 2009)
Model 1
Model 2
Model 3
23 (21)
10 (9)
8 (8)
23 (22)
13 (18)
14 (18)
25 (24)
29 (24)
28 (23)
26 (27)
29 (27)
27 (27)
23 (27)
31 (30)
32 (30)
28 (31)
33 (32)
37 (33)
26 (29)
34 (34)
31 (36)
37 (34)
33 (36)
34 (37)
39 (37)
37 (40)
38 (39)
40 (38)
41 (40)
41 (39)
0.69

0.32

0.13

Number with Observed (Predicted) Good PS (Post 2009)
Model 1
Model 2
Model 3
28 (28)
12 (12)
10 (12)
29 (30)
22 (24)
24 (24)
34 (33)
32 (30)
32 (30)
37 (36)
33 (33)
34 (33)
32 (34)
38 (36)
36 (36)
34 (35)
40 (38)
37 (37)
39 (37)
35 (38)
39 (39)
42 (42)
42 (40)
39 (40)
36 (37)
41 (42)
41 (42)
25 (23)
41 (41)
44 (43)
0.92

0.63

0.98

Deciles were created by ranking patients according to increasing predicted likelihood of good
performance status on the basis of the explanatory variables in each of the three models.
2
Pre 2009: Good PS = ECOG: 0 – 1 or KPS: 80 – 100 / Poor PS = ECOG: 2 – 5 or KPS: 0 – 70.
3
Post 2009: Good PS = ECOG: 0 – 2 or KPS: 60 – 100 / Poor PS = ECOG: 3 – 5 or KPS: 0 – 50.
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2.4 Discussion
Among a contemporary cohort of patients with stage II through IV lung
cancer, explicit medical record documentation of PS was found less than half the
time (47%). Review of nursing and physician notes led PS to be determinable via
medical records approximately 80% of the time. Given the central role that PS
plays in clinical decision-making among patients with lung cancer, the lack of
consistent medical record documentation is troubling. When documented, we
found the distribution of PS among the cohort (34% with poor PS [when a PS of 2
was considered as having poor PS]) to be identical to the 34% with poor PS
reported by Lilenbaum et al in contemporary clinical studies (R. C. Lilenbaum et
al. 2008).
It was found that poor PS among lung cancer patients with stage III to IV
disease can be predicted reasonably well regardless of whether a PS of 2 is
considered good or poor. Furthermore, this was true regardless of the level of
comprehensiveness of the data used, but particularly for models that used
information routinely available in medical claims data or medical and
pharmaceutical claims data combined, in which the c statistics were all >0.70.
Although the inclusion of information routinely available in medical claims data
marginally improved model fit and predictive accuracy when compared with a
model fit using only data available in tumor registries, the inclusion of information
from pharmaceutical claims data did not appear to substantively alter model fit,
regardless of how good PS is defined.
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To my knowledge, this is the first study to use observational data to
estimate PS for lung, or any other, cancer patients. As such, these findings
represent a significant contribution to the field. These findings are important for
the ability to monitor quality of care and the appropriateness of chemotherapy,
and the ability to prospectively identify patients who may be appropriate (but not
targeted) for clinical trial or palliative care/hospice enrollment without relying on
expensive and time-consuming primary data collection methods. Predictive
models such as those presented herein that rely on data routinely available
within large, observational databases can also be used to augment comparative
effectiveness research, including comparisons of different chemotherapy
regimens as well as the receipt of chemotherapy versus non-chemotherapy
treatment and thereby greatly enhance the capabilities of existing electronic
databases such as that available via Surveillance, Epidemiology, and End
Results (SEER)-Medicare data.
Although these findings of significant differences in chemotherapy receipt
by good versus poor PS add face validity to the accuracy of the PS score
abstracted from the medical record, the finding that approximately 42% of
patients with medical record-documented poor PS received chemotherapy in the
year after diagnosis highlights the importance of attempts such as ours to make
documented PS or PS proxies more readily available to those who monitor and
study cancer care quality and outcomes. At the time of this study, national clinical
practice guidelines for patients with non-small cell lung cancer unequivocally
recommended chemotherapy for patients with a PS of 0 or 1 (1997;D. G. Pfister
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et al. 2004). These guidelines suggested that chemotherapy might ‘‘possibly’’ be
of benefit in patients with a PS of 2, noting that those patients had been excluded
from clinical trials. This was in keeping with expert opinions of the time (E.
Rodriguez, R. C. Lilenbaum 2008). More recent data have shown survival and
quality of life benefits for patients with a PS of 2, although less than with good
PS, and the most recent ASCO guidelines are more supportive of chemotherapy
for patients with a PS of 2 (C. G. Azzoli et al. 2009). Routine chemotherapy
among lung cancer patients with a PS ≥ 3 continues to not be recommended by
any national professional organization. Chemotherapy use in patients with little
chance of benefit and more chance of toxicity may delay discussion about
prognosis and dying (A. A. Wright et al. 2008), which may lead to further poor
quality of care, such as the inappropriate use of mechanical ventilation or delays
in referral to hospice, worse surviving caregiver quality of life, and high end-of-life
care costs (B. Zhang et al. 2009). Without PS proxies, little can be done to use
automated data sources to monitor and measure either the underuse or overuse
of chemotherapy and its implications on patient and economic outcomes.
The results of the current study should be interpreted in light of the
following limitations. First, subjectivity is present in the assignment of PS. Even
when assessed by a healthcare professional, PS scales are subjective in nature
(K. Kelly 2004) and when estimated by physicians are known to be prone to error
(C. Zimmermann et al. 2010), usually being overestimated (R. C. Lilenbaum et al.
2008). Thus, even if this model were 100% accurate, caution would have to be
used in interpreting results dependent on an accurate classification of PS.
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Nonetheless, the ability to develop a useful proxy measure of PS from existing
observational data will help in the use of existing national data resources such as
that available with SEER Medicare data for comparative effectiveness research.
Second, these models were developed on a relatively small sample and one that
is specific to 1 delivery system. Therefore, not only should care be taken when
generalizing findings, but the parsimonious models may exclude important
predictors of PS available in observational data. Finally, identifying patients with
poor PS by their diagnoses and use of care via claims data poses its own
limitations. For example, DME use varies significantly based on differing personal
preferences and practices in addition to restrictions on reimbursement by public
and private insurers. Although claims for DME offer useful information, they
identify only selected people with potentially disabling conditions (L. I. Iezzoni
2003). The same is true of medical diagnoses, many of which are known to be
under captured in medical claims data, and prescription drug dispensing, which
reflects only those medications prescribed by physicians that the patient elected
to fill. Nevertheless, the ability to proxy PS is critical to the ability to use
observational data to accurately draw conclusions regarding comparative
effectiveness and cancer care quality at a population level if not at the bedside.
Despite these limitations, results from the current study shed new light on
the capacity of information routinely available in observational data to identify
lung cancer patients with good versus poor PS. This is especially useful for
researchers interested in leveraging existing observational databases for
comparative effectiveness research. Recent studies have highlighted a likely
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overuse of chemotherapy in the treatment of patients with lung cancer as well as
aggressive treatment near the end of life (C. C. Earle et al. 2004;R. Matsuyama
et al. 2006;S. E. Harrington, T. J. Smith 2008). Using a predictive model such as
the one developed herein with a threshold of 0.70 to proxy a patient as having
poor PS would ensure reasonably high specificity (0.69 if a PS of 2 is considered
poor) and thereby enable the identification of a population for whom the receipt of
chemotherapy appears inadvisable or requiring a more tailored discussion of less
benefit and more risk per current guideline recommendations, and for whom
early hospice intervention may be warranted. Conversely, using a lower
predictive threshold (0.50) and thereby increasing the sensitivity of the predictive
model may be useful to health disparities researchers, in whom interest might be
in testing a hypothesis centered on under treatment among minority populations.
Similarly, choosing a predictive threshold with a high sensitivity could facilitate
population identification for observational comparative effectiveness research.
The best selection of both a predictive threshold and the allocation of patients
with a PS of 2 will ultimately depend on the user’s objectives.
PS has long been considered one of the strongest prognostic factors (K.
S. Albain et al. 1991) and is used today by clinicians to assess the
appropriateness of chemotherapy and regimen choice for patients with lung
cancer (C. G. Azzoli et al. 2009). With the aging population, the number of
Americans with functional limitations will increase dramatically, and therefore the
urgency to capture and classify information regarding functional status will grow
(L. I. Iezzoni, M. S. Greenberg 2003). Furthermore, given the current challenges
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faced by the US healthcare system to deliver better and more cost-effective
outcomes, the importance of comparative effectiveness studies is likely to only
grow. To the best of my knowledge, the results of the current study are the first to
provide health services researchers and others with a viable tool with which to
predict PS among lung cancer patients using information routinely available in
observational data. As such, the value of observational data for comparative
effectiveness research and for use by those interested in understanding cancer
care quality or targeting specific lung cancer patients for possible inclusion in
clinical trials, hospice care, or other interventions is greatly enhanced.
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CHAPTER 3. FACTORS ASSOCIATED WITH ADHERENCE TO
CHEMOTHERAPY GUIDELINES IN PATIENTS WITH LUNG
CANCER
Evidence-based guidelines recommend chemotherapy for medically fit
patients with stage II-IV non-small cell lung cancer (NSCLC). Adherence to
chemotherapy guidelines has rarely been studied among large populations,
mainly because performance status (PS), a key component in assessing
chemotherapy appropriateness, is missing from claims-based or other automated
datasets. Among a large cohort of patients with known PS, chemotherapy use is
described relative to guideline recommendations and patient factors associated
with guideline concordant use are identified.
Insured patients, ages 50+, diagnosed with stage II-IV NSCLC between
2000-2007 were identified via tumor registry (n=406). Chart abstracted PS,
automated medical claims, Census tract information, and travel distance were
linked to tumor registry data. Chemotherapy was appropriate for patients with PS
0-2. Multivariate logit models were fit to evaluate patient characteristics
associated

with

chemotherapy

over-

and

under-use

per

guideline

recommendations.
Overall compliance with chemotherapy guidelines was 71%. Significant
(p<0.05) predictors of chemotherapy underuse (19%) included increasing age
(odds ratio [OR], 1.09), higher income (OR, 1.02), diagnosed before 2003 (OR,
2.05), and vehicle access (OR, 6.96) in the patient’s neighborhood. Significant
predictors of chemotherapy overuse (10%) included decreasing age (OR, 0.92),
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diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the patient’s
neighborhood.
Among NSCLC patients 29% do not receive guideline recommended
chemotherapy

treatment,

missing

opportunities

for

cure

or

receiving

chemotherapy with more risk of harm than benefit, thereby likely foregoing
beneficial palliation. Care concordant with guidelines is influenced by age, and
economic considerations, such as income, and transportation barriers.

3.1 Introduction
Evidence-based

treatment

guidelines

recommend

the

use

of

chemotherapy for medically fit patients with unresectable or stage IV non-small
cell lung cancer (NSCLC) to improve survival, symptoms, and quality of life
(1997;2010b;D. G. Pfister et al. 2004;2010c). Despite these recommendations,
studies in the past decade have documented variability in the receipt of
chemotherapy among patients with NSCLC (T. J. Smith et al. 1995;P. B. Bach et
al. 1999;C. C. Earle et al. 2000;A. L. Potosky et al. 2004). Understanding the
extent to which chemotherapy use in practice is consistent with these guidelines,
as well as the factors associated with inappropriate chemotherapy use has rarely
been studied among large populations, mainly because performance status (PS),
a key clinical component in assessing chemotherapy appropriateness, is typically
missing from claims-based databases.
Determining whether care meets professional standards is important in
lung cancer care. Adherence to evidence-based guidelines has been used to
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assess the quality of health care for a wide range of conditions (M. A. Schuster et
al. 2005), so it is natural to ask how often lung cancer care agrees with guideline
recommended care. Previous studies suggest that chemotherapy is sometimes
overused at the end of life, with 20% (C. C. Earle et al. 2004) to 43% (J. R.
Murillo, Jr., J. Koeller 2006) or more of lung cancer patients receiving
chemotherapy within just a few weeks of a patient’s death. Yet, lung cancer
patients who use hospice for at least one day – thus avoiding chemotherapy
during their stay in hospice, and getting appropriate symptom management –
have been shown to live significantly longer than lung cancer patients who never
use hospice.(S. R. Connor et al. 2007) Recent studies show that at 2 months
before their death, half of the doctors of lung cancer patients have not even
mentioned hospice options (H. A. Huskamp et al. 2009), and the average
hospice length of stay is only 4 days (J. S. Temel et al. 2010). At the same time,
an underuse of curative surgery, combined chemotherapy and radiation (P. B.
Bach et al. 1999;T. J. Smith et al. 1995) and palliative chemotherapy may
unnecessarily increase the symptom burden and the death rate from this
disease.
The issue of guideline adherence has been more comprehensively
examined in breast cancer research where a number of studies have
demonstrated improvement in survival when patients were treated according to
clinical practice guidelines (A. Olivotto et al. 1997;N. Hebert-Croteau et al.
2004;T. L. Lash et al. 2000;T. L. Lash et al. 2005). Several breast cancer studies
have found that increased age, comorbidity, black race, lower educational
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attainment, and advanced disease stage are associated with receipt of
nonstandard treatment regimens (usually underuse or use of reduced doses),
which in turn contributes to less favorable outcomes (J. J. Griggs et al. 2007;N.
A. Bickell et al. 2006;D. Hershman et al. 2005;N. A. Bickell et al. 2009;N. Krieger
1992). Furthermore, a conceptual model that explains the underuse of effective
therapy in breast cancer has been proposed, where therapy underuse is
explained by the interaction of patient, physician, and system factors, each of
which exists within a health care system and an individual’s community (N. A.
Bickell 2002).
The purpose of this research is to quantify the extent of adherence to
evidence-based guidelines for use of chemotherapy among an insured
population diagnosed with NSCLC between 2000 and 2007 with medical record
documented PS, and to evaluate the factors associated with both the under- and
over-use of chemotherapy within this cohort. By combining data from patients’
medical records with those available via an automated tumor registry, medical
claims, and Census data, this study is able to consider the patients’ clinical and
socio-demographic characteristics, as well as the characteristics of the
neighborhood in which they reside and how they are associated with use
consistent with guidelines.
Studies of chemotherapy use for NSCLC in the past have neglected PS, a
clinically important measure in the assessment of appropriateness of
chemotherapy. The present study contributes to the literature by explicitly
accounting for a patient’s PS. In so doing, it is able to accurately quantify the
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extent and nature of deviations from treatment guidelines, and to quantify the
patient characteristics associated with both under- and overuse of chemotherapy.
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3.2 Methods
Study Population and Setting
Study patients were those receiving care from a 900-physician member,
multispecialty, salaried medical group practice in southeast Michigan. Data
available from the medical group’s tumor registry were used to identify all
patients aged ≥ 50 years who were diagnosed with NSCLC between January 1,
2000 and December 31, 2007. The medical group, which provides care under
both fee-for-service and capitated arrangements, staffs 27 primary care clinics
throughout Detroit and the surrounding metropolitan area. Patients eligible for
study inclusion were those continuously enrolled in an affiliated health plan (ie,
health maintenance organization) for the 1-year period preceding their date of
lung cancer diagnosis. Patients for whom no stage of disease was available or
for whom the stage at diagnosis was 0 or I were excluded. The latter were
excluded because chemotherapy was not indicated for patients with stage 0 or I
disease during this time period (W. J. Scott et al. 2007). Patients who died within
one month of their diagnosis were also excluded from the study. The medical
group’s Institutional Review Board approved all aspects of the study protocol.

Primary Outcome of Interest
Per the American Society of Clinical Oncology (ASCO) clinical practice
guidelines issued in 2009 (C. G. Azzoli et al. 2009), chemotherapy was
recommended for patients with good PS (i.e., PS= 0-2) and not recommended for
patients with poor PS (i.e., PS=3-4). Earlier ASCO guidelines had recommended
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chemotherapy for patients with PS 0-1 only.(1997) In model estimations I include
patients with PS=2 in the good PS group. Alternative models that instead include
PS 2 patients in the poor PS group were also estimated, and are included in
Appendix A. Throughout, instances in which patients with good PS did not
receive chemotherapy were classified as “underuse,” while instances in which
patients with poor PS received chemotherapy were classified as “overuse.”
Two trained chart abstractors reviewed inpatient and outpatient nursing
and physician notes available within the patient’s electronic medical record from
2 months before diagnosis until the first notation of death, disenrollment, initiation
of chemotherapy, or 6 months after diagnosis to obtain PS. Abstractors
documented specific numeric PS, if available, or an estimated PS based on
medical notes. In the latter case, notes regarding the patient’s functionality (e.g.,
references to shortness of breath, use of a wheelchair or other personal mobility
devices, labor force participation, exercising habits, activities of daily living, or
other references to mobility) were recorded and used to estimate PS. Inter-rater
reliability between the 2 abstractors was assessed on a random subset of 40
observations and the resulting Cohen κ was 0.88.

Automated Tumor Registry and Claims Data
Automated tumor registry and claims data were accessed to obtain patient
demographic characteristics, date of cancer diagnosis, stage at diagnosis, and
comorbidities in the 12-month period preceding diagnosis for each patient.
Patient demographics included age, gender, and race. The age of the patient (in
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years) was recorded as of the date of lung cancer diagnosis. Clinical measures
for each patient included stage of disease at the time of diagnosis and the
Charlson comorbidity index (M. E. Charlson et al. 1987). Cancer stage was
reported using the American Joint Committee on Cancer (AJCC) stages II
through IV. The Deyo adaptation of the Charlson comorbidity index and each of
its component diagnostic subgroups were constructed using inpatient and
outpatient diagnostic information available in the 12-month period preceding
diagnosis (R. A. Deyo et al. 1992).

Socioeconomic Data
Socioeconomic information, including education level, median household
income, and vehicles per household were obtained from the 2000 US Census.
Using patients’ residential street address, Census tract level data were used to
characterize the socioeconomic profile of each patient’s neighborhood of
residence. MapPoint (2010; Microsoft Corporation, Redmond, WA) was used to
calculate the travel distance between each patient’s home and the nearest
chemotherapy facility that was affiliated with the group practice.

Statistical Analysis
Patients were assigned into 4 distinct groups: patients with good PS who
received

chemotherapy;

patients with

good PS

who

did not

receive

chemotherapy; patients with poor PS who received chemotherapy; and patients
with poor PS who did not receive chemotherapy. Systematic unadjusted
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differences between patients receiving chemotherapy and those who did not
receive chemotherapy, within the good PS and poor PS groups (patients in the
first two groups and patients in the latter two groups) were examined, using 2sample Student t tests (or Wilcoxon rank sum tests) and chi-square tests,
depending on the nature of the characteristic. Two multivariate logistic regression
models were fit to evaluate the factors associated with receipt of chemotherapy,
given the patient’s PS. The first model estimated chemotherapy receipt among
patients with good PS (i.e., evaluated factors associated with chemotherapy
under use) while the second model estimated chemotherapy receipt among
patients with poor PS (i.e. evaluated factors associated with chemotherapy
overuse). Both models controlled for patient age at diagnosis, gender, race, and
comorbidities as well as the college graduation rate, median household income,
and vehicle access in their neighborhood, distance to nearest chemotherapy
facility, and year of diagnosis.
SAS statistical software (version 9.1.3; SAS Institute Inc, Cary, NC) was
used for all analyses. P < .05 was considered to be statistically significant.

3.3 Results
Cohort Characteristics
A total of 406 patients met the criteria for study eligibility. Overall sample
characteristics are reported in Table 6. The mean age of the cohort was 67.4
years (standard deviation [SD], 8.9 years). Just under half (41%) were female,
whereas the racial distribution was 69% white, 29% black, and 2% of other races.
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The AJCC staging distribution was as follows: 11% of patients were diagnosed
with stage II disease, 41% were diagnosed with stage IIII disease, and 48% were
diagnosed with stage IV disease. The average Charlson comorbidity index
across the sample was 1.3 (SD, 1.6).
At the Census tract level, the mean college graduation rate for the cohort
was 6.9% (SD, 5.6), the median household income (in 2000) was $49,200 (SD,
21,900), and 12.2% (SD, 19.0) of residents lived in households that had no
vehicles. The average travel distance of patients to the nearest chemotherapy
facility was 10.8 miles (SD, 11.7).
Across the sample, 13% of patients received no anti-cancer treatment for
their lung cancer, 1% received surgery only, 16% received radiation therapy only,
13% received chemotherapy only, 5% received a combination of surgery and
chemotherapy but no radiation, 44% received radiation and chemotherapy but no
surgery, and 8% received all three modes of treatment.
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Table 6. Overall Sample Characteristics, Lung Cancer Patients with Stages II-IV
(n = 406)

Demographic Characteristics
Average age at diagnosis (SD)
Gender (%)
Female
Male
Race (%)
Black
White
Other
Clinical Characteristics
AJCC stage (%)
II
III
IV
Average Charlson comorbidity index (SD)
Socioeconomic Characteristics
Pct with college degree (SD)
Median household income in $1000s (SD)
Access to Treatment
Pct without vehicle (SD)
Distance (miles) to chemotherapy facility (SD)
Treatment(s) Received
No treatment (%)
Surgery only (%)
Radiation therapy only (%)
Chemotherapy only (%)
Surgery + radiation therapy (%)
Surgery + chemotherapy (%)
Radiation + chemotherapy (%)
Surgery + radiation + chemotherapy (%)

67.4 (8.9)
41
59
29
69
2

11
41
48
1.3 (1.6)
6.9 (5.6)
49.2(21.9)
12.2(19.0)
10.8(11.7)
13
1
16
13
0
5
44
8
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Chemotherapy Receipt by Performance Status
Table 7 reports chemotherapy receipt by stage and PS. Overall, 77
patients (19%) with good PS did not receive chemotherapy, while 39 patients
(10%) with poor PS received chemotherapy. Among patients diagnosed with
stage II disease, 9 (20%) with good PS did not receive chemotherapy and 6
(14%) with poor PS received it. Among those diagnosed with stage III disease,
31 (19%) with good PS did not receive chemotherapy and 9 (5%) with poor PS
received it. Among those diagnosed with stage IV disease, 37 (19%) with good
PS did not receive chemotherapy and 24 (12%) with poor PS received it.
Table 8 reports the unadjusted differences in cohort characteristics
between patients receiving chemotherapy and those not receiving it, across 2
groups: patients with good PS and poor PS. Among patients with good PS, there
were significant differences between those receiving chemotherapy and those
not receiving it by age at diagnosis, the patient’s Charlson comorbidity index, and
the vehicle ownership rate in the patient’s neighborhood. Among patients with
poor

PS,

there

were

significant

differences

between

those

receiving

chemotherapy and those not receiving it by age and median household income in
the patient’s neighborhood.
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Table 7. Chemotherapy Receipt by Performance Status (PS), (N = 406)

Chemotherapy
Received?
Yes
No
All Cases, (N = 406)
0-1
213(52%)
ECOG PS
2
30 (7%)
3-4
39 (10%)
Stage II, (N = 44)
0-1
25 (57%)
ECOG PS
2
1 (2%)
3-4
6 (14%)
Stage III, (N = 165)
0-1
99 (60%)
ECOG PS
2
8 (5%)
3-4
9 (5%)
Stage IV, (N = 197)
0-1
89 (45%)
ECOG PS
2
21 (11%)
3-4
24 (12%)

63 (16%)
14 (3%)
47 (12%)
9 (20%)
0 (0%)
3 (7%)
25 (15%)
6 (4%)
18 (11%)
29 (15%)
8 (4%)
26 (13%)
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Table 8. Sample Characteristics, by Performance Status (PS) and Choice of
Chemotherapy Receipt or Non-Receipt, for Lung Cancer Stages II-IV (n = 406)
Good PS1 (n = 320)

Demographic Characteristics
Average age at diagnosis (SD)
Gender (%)
Female
Male
Race (%)
Black
White
Other
Clinical Characteristics
AJCC stage (%)
II
III
IV
Average Charlson comorbidity index (SD)
Socioeconomic Characteristics
Pct with college degree (SD)
Median household income in $1000s (SD)
Access to Treatment
Pct without vehicle (SD)
Distance (miles) to chemotherapy facility
(SD)
Treatment(s) Received
No treatment (%)
Surgery only (%)
Radiation therapy only (%)
Chemotherapy only (%)
Surgery + radiation therapy (%)
Surgery + chemotherapy (%)
Radiation + chemotherapy (%)
Surgery + radiation + chemotherapy (%)

1

Poor PS2 (n = 86)

Chemo
(n = 243)

No Chemo
(n = 77)

Chemo
(n = 39)

No Chemo
(n = 47)

65.5 (8.5)3

71.4 (8.9)3

66.9 (9.0)4

71.1 (7.5)4

41
59

47
53

36
64

36
64

26
72
2

30
66
4

31
69
0

36
58
6

11
44
45
1.0 (1.4)3

12
42
48
1.4 (1.5)3

15
23
62
1.9 (2.0)

6
39
55
2.3 (2.3)

7.1 (6.0)
50.4(22.2)

6.1 (4.9)
47.6(19.8)

6.7 (5.9)
52.4(27.8)4

6.9(4.4)
42.7(16.6)4

10.0(15.1)3
11.3(13.6)

15.9(21.8)3
10.6 (8.7)

12.8(17.7)
9.5 (8.0)

16.3(29.3)
9.6 (6.4)

17
8
62
13

42
5
52
1
-

31
64
5

45
2
53
-

Good PS: ECOG 0-2
Poor PS: ECOG>2
3
Among patients with good PS, significant difference by chemotherapy receipt/non-receipt, at 5%
level
4
Among patients with poor PS, significant difference by chemotherapy receipt/non-receipt, at 5%
level
2
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Factors Associated with the Non-Receipt of Chemotherapy among Patients
with Good Performance Status
Results from the multivariable logistic regression model for factors
associated with the non-receipt of chemotherapy among patients with good PS
are presented in Table 9.

As indicated in the model, patients who are

significantly less likely to receive chemotherapy when the PS is good include
older patients, patients residing in neighborhoods with higher median household
income, and those living in neighborhoods with a higher percentage of
households without any vehicle. At the same time, patients who are more likely
to receive chemotherapy when their PS is good include patients residing in
neighborhoods with a higher percentage of college graduates and patients
diagnosed in 2003 or later. Factors that were not significant in this model
included gender, race, comorbidities, and distance to nearest chemotherapy
facility.

Factors Associated with the Receipt of Chemotherapy among Patients with
Poor Performance Status
Table 10 reports the results of the logistic regression model for
chemotherapy receipt among patients with poor PS. Factors that were
associated with significantly higher odds of chemotherapy receipt when PS is
poor include median household income and being diagnosed in 2003 or later.
Older patients and those who lived in neighborhoods with a higher percentage of
college graduates are less likely to receive chemotherapy when they have poor
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PS. Factors that were not significant in this model included gender, race,
comorbidities, vehicle access, and distance to nearest chemotherapy facility.
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Table 9. Factors Associated with Non-Receipt of Chemotherapy among Patients
with Good Performance Status (PS), for Lung Cancer Stages II-IV (N = 320)
Performance Status = Good1
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Access to Treatment
Pct without vehicle
Distance to chemo facility
Guidelines
Year of diagnosis < 2003
Model Performance
Pseudo-R2
C-statistic

1

Good PS: ECOG 0-2

Odds of Under Use (95% CI)

P Value

1.09 (1.05-1.13)
1.35 (0.77-2.37)
0.75 (0.36-1.58)

<0.01
0.29
0.46

1.16 (0.96-1.39)

0.13

0.93 (0.86-1.00)
1.02 (1.00-1.04)

0.07
0.05

6.96(1.00-49.34)
1.00 (0.99-1.03)

0.05
0.50

2.05 (1.17-3.62)

0.01
0.13
0.74
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Table 10. Factors Associated with Receipt of Chemotherapy among Patients with
Poor Performance Status (PS), for Lung Cancer Stages II-IV (N = 86)
Performance Status = Poor1
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Access to Treatment
Pct without vehicle
Distance to chemo facility
Guidelines
Year of diagnosis ≥ 2003
Model Performance
Pseudo-R2
C-statistic

1

Poor PS: ECOG>2

Odds of Over Use (95% CI)

P Value

0.92 (0.86-0.98)
0.87 (0.32-2.38)
0.83 (0.24-2.85)

0.01
0.79
0.77

1.01 (0.78-1.32)

0.92

0.89 (0.78-1.02)
1.05 (1.01-1.10)

0.08
0.02

3.41(0.25-46.81)
0.97 (0.90-1.04)

0.36
0.38

3.24 (1.07-9.85)

0.04
0.19
0.75
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3.4 Discussion
Using a large cohort of patients with lung cancer for whom PS is known,
this study found the overall adherence to evidence-based guidelines for
chemotherapy treatment to be 71%.

Among those whose care was non-

concordant with guideline recommendations, 19% did not receive chemotherapy
when it was indicated and 10% received chemotherapy when it was not
recommended. This study recorded a higher adherence rate than a previous lung
cancer study that used population-based Medicare data and did not control for
PS (A. L. Potosky et al. 2004). This study finds that older patients are less likely
to use chemotherapy, regardless of their PS. That is, among patients with good
PS, older patients are less likely to receive recommended chemotherapy, and
among patients with poor PS, they are also less likely to receive chemotherapy.
While the latter likely implies high quality care, the former does not. Variations in
the receipt of chemotherapy by age are consistent with findings from a previous
study (A. L. Potosky et al. 2004). Whether this is a result of patient preferences
or barriers, physician bias, or a combination of these is not known.
The higher the median household income in the patient’s neighborhood of
residence the more likely they are to be out of compliance in both directions, both
“overusing” and “underusing” chemotherapy. As with the findings of differences in
chemotherapy use by patient age, this study is not able to determine the extent
to which observed utilization is a result of patient preferences or barriers,
physician bias or a combination of these.
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Unlike other studies that analyzed Medicare claims data, this research
considered a rarely studied managed care cohort that included younger patients
as well as older ones. Another notable difference is that this study found no racial
differences were found in the receipt of chemotherapy (either underuse or
overuse). This difference may be attributable to two factors. First, the study
population consisted of patients who received their care through a managed care
plan, whereas previous studies have focused mainly on seniors with traditional
Medicare (i.e., Parts A and B), not enrolled in a Medicare managed care plan
(i.e., Part C). Research suggests that managed care plans reduce health care
disparities, at least for broadly defined measures of access to care (A. I. Balsa et
al. 2007). Second, unlike prior studies (P. B. Bach et al. 1999;A. L. Potosky et al.
2004;T. J. Smith et al. 1995), this one was able to control for a patient’s PS as
well as several socioeconomic characteristics at the census tract level, i.e.,
education, income, and car ownership. It may not be race, per se, that leads to
previously documented treatment disparities, but rather PS and socioeconomic
characteristics, both of which are highly correlated with race.
Finally, among the urban/suburban population studied here, travel
distance was not found to be associated with recommended chemotherapy
treatment.

Instead, the study found that if fewer households in a patient’s

neighborhood had access to a car, this travel barrier was associated with
underuse of chemotherapy relative to guideline recommendations. This finding
implies that even among a non-rural population, the presence of transportation
barriers is an important predictor of the underuse of chemotherapy among
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patients with good PS. Thus, despite the health system in which this study was
conducted having multiple and geographically dispersed clinics that offer
chemotherapy treatment, these findings suggest that patients without access to
a car may have difficulty reaching a clinic, even when there is a clinic a relatively
short distance from their home.
The results of the current study should be interpreted in light of the
following limitations. First, these findings are based on a cohort of insured cancer
patients, and adherence rates as well as the factors associated with them may
differ among an uninsured population. Similarly, models were developed on a
sample of patients receiving their care from one delivery system located in a
large urban area. Therefore, care should be taken when generalizing findings to
other delivery settings and locales. Likewise, models may exclude important
factors associated with chemotherapy receipt including provider characteristics
and variations across health systems and geographical regions. However, the
average age and other characteristics of this cohort are similar to the whole U.S.
Finally, this study was not intended to assess appropriateness of specific
chemotherapy regimens, and further, it is not known whether chemotherapy was
given with good intent in lieu of hospice for palliative reasons to those with poor
PS, and if there was any subsequent impact on symptom burden or
hospitalizations for side effects.
In summary, about 71% of patients in an insured population received
chemotherapy

concordant

with

guideline

recommendations

based

on

performance status, but 29% did not. There will be over 222,000 people
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diagnosed in the U.S. with lung cancer in 2011 (American Cancer Society 2010).
Given the effectiveness of modern chemotherapy for palliation and prolonged
survival, 19% of patients almost certainly did not live as long or as well as they
might have with chemotherapy, and about 10% of patients received
chemotherapy that had little chance of benefit and excess risk of toxicity
including hospitalizations, excess cost, and delay of entry into hospice.
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CHAPTER 4. ADHERENCE TO CHEMOTHERAPY GUIDELINES
AND SURVIVAL AMONG PATIENTS WITH LUNG CANCER
Evidence-based guidelines recommend chemotherapy for medically fit
patients with stage II-IV non-small cell lung cancer (NSCLC). The relationship
between adherence to chemotherapy guidelines and overall survival is not
known. Insured patients, ages 50+, diagnosed with stage II-IV NSCLC between
2000-2007 were identified via tumor registry (n=406). Chart abstracted
Performance Status (PS), automated medical claims, and Census tract
information were linked to tumor registry data. Chemotherapy was appropriate for
patients with PS 0-2. Kaplan Meier estimates were used to describe survival
differences by PS and choice of chemotherapy. Multivariate Cox logistic
regression analysis was used to determine the factors associated with treatment
outcome.
Guideline adherent use of chemotherapy reduced risk of dying (hazard
ratio [HR], 0.64). Other factors associated with survival among good PS patients
(p<0.05) include surgery (HR, 0.33), female gender (HR, 0.66), and stage IV
disease (HR, 2.19). Overuse of chemotherapy also reduced risk of dying (HR,
0.04). Among poor PS patients, stage IV diagnosis was also associated with
higher risk of death (HR, 1.90). Chemotherapy has positive effects on survival for
both good and poor PS patients. In the poor PS group, the relationship between
chemotherapy and survival may be affected by other unobservable factors.
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4.1 Introduction
Lung cancer is the second most common cancer diagnosed in the United
States and is the leading cause of cancer-related deaths, with an estimated
222,520 new cases and 157,300 deaths in 2010. The economic cost of lung
cancer is high, with an estimated cost of $10 billion per year.(American Cancer
Society 2010) Non-small cell lung cancer (NSCLC) makes up approximately 85%
of lung cancer cases in the United States. Because of the incidence, severity,
and rising costs, it is becoming increasingly important to deliver consistent, highquality, cost-effective care for NSCLC.
Evidence-based

treatment

guidelines

recommend

the

use

of

chemotherapy for medically fit patients with unresectable or stage IV NSCLC to
improve survival, symptoms, and quality of life (1997;2010b;2010c;D. G. Pfister
et al. 2004). Despite these recommendations, studies in the past decade have
documented variability in the receipt of chemotherapy among patients with
NSCLC (P. B. Bach et al. 1999;C. C. Earle et al. 2000;A. L. Potosky et al.
2004;T. J. Smith et al. 1995).
Due to improvements in surgical techniques and combined therapies,
survival for lung cancer patients has improved in the last 2 decades. Despite
these advancements, the 1-year relative survival for lung cancer is just over 40%,
while the 5-year survival for NSCLC remains at 17%. Although overall survival is
documented by stage, gender, and other clinical and demographic characteristics
in studies that have demonstrated significant benefits of chemotherapy (S. D.
Ramsey et al. 2004;2008), the relationship between adherence to chemotherapy
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guidelines and survival is not known. This is largely due to the fact that measures
of PS, a key factor in evaluating the appropriateness of chemotherapy, are
currently not available though automated medical claims, tumor registries, or
other observational data commonly used to study cancer treatment and its
associated outcomes.
The purpose of this research is to examine survival of insured patients
diagnosed with NSCLC in relation to adherence to chemotherapy guidelines,
controlling for other patient clinical and socio-demographic characteristics. By
combining data from medical records with those available via an automated
tumor registry, medical claims, Census data, and chart-abstracted PS, this study
is able to consider the patients’ clinical and socio-demographic characteristics as
well as adherence to chemotherapy guidelines in measuring effects on survival.

4.2 Methods
Study Population and Setting
Study patients were those receiving care from a 900-physician member,
multispecialty, salaried medical group practice in southeast Michigan. Data
available from the medical group’s tumor registry were used to identify all
patients aged ≥ 50 years who were diagnosed with NSCLC between January 1,
2000 and December 31, 2007. The medical group, which provides care under
both fee-for-service and capitated arrangements, staffs 27 primary care clinics
throughout Detroit and the surrounding metropolitan area. Patients eligible for
study inclusion were those continuously enrolled in an affiliated health plan (ie,
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health maintenance organization) for the 1-year period preceding their date of
lung cancer diagnosis. Patients for whom no stage of disease was available or
for whom the stage at diagnosis was 0 or I were excluded. The latter were
excluded because chemotherapy was not indicated for patients with stage 0 or I
disease during this time period (W. J. Scott et al. 2007). Patients who died within
one month of their diagnosis were also excluded. The medical group’s
Institutional Review Board approved all aspects of the study protocol.

Performance Status (PS) and Guideline Adherence
Instances in which patients with good PS did not receive chemotherapy
were classified as “underuse,” while instances in which patients with poor PS
received chemotherapy were classified as “overuse.” Per the American Society
of Clinical Oncology (ASCO) clinical practice guidelines issued in 2009 (C. G.
Azzoli et al. 2009), chemotherapy was recommended for patients with good PS
(i.e., PS= 0-2) and not recommended for patients with poor PS (i.e., PS=3-4).
Earlier ASCO guidelines had recommended chemotherapy for patients with
PS=0-1 only.(1997) The baseline models included patients with PS=0-2 in the
good PS group. Alternative models that considered PS=2 patients with the poor
PS group were also evaluated. Two trained chart abstractors reviewed inpatient
and outpatient nursing and physician notes available within the patient’s
electronic medical record from 2 months before diagnosis until the first notation
of death, disenrollment, initiation of chemotherapy, or 6 months after diagnosis to
obtain PS. Abstractors recorded the PS documented closet to the diagnosis date.
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If no specific PS was documented, they estimated PS based on medical notes. In
the latter case, notes regarding the patient’s functionality (e.g., references to
shortness of breath, use of a wheelchair or other personal mobility devices, labor
force participation, exercising habits, activities of daily living, or other references
to mobility) were recorded and used to estimate PS. Inter-rater reliability between
the 2 abstractors was assessed on a random subset of 40 observations and the
resulting Cohen κ was 0.88.

Automated Tumor Registry and Claims Data
Automated tumor registry and claims data were accessed to obtain patient
demographic characteristics, date of cancer diagnosis, stage at diagnosis, and
comorbidities in the 12-month period preceding diagnosis for each patient.
Patient demographics included age, gender, and race. The age of the patient (in
years) was recorded as of the date of lung cancer diagnosis. Clinical measures
for each patient included stage of disease at the time of diagnosis and the
Charlson comorbidity index (M. E. Charlson et al. 1987). Cancer stage was
reported using the American Joint Committee on Cancer (AJCC) stages II
through IV. The Deyo adaptation of the Charlson comorbidity index and each of
its component diagnostic subgroups were constructed using inpatient and
outpatient diagnostic information available in the 12-month period preceding
diagnosis (R. A. Deyo et al. 1992). The date of death was obtained from the
tumor registry.
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Claims data were also used to identify treatment types, including receipt of
chemotherapy, surgery, and/or radiation therapy. Because NSCLC has a very
high short-term mortality rate, initial treatment (chemotherapy, surgery, or
radiation therapy) was defined by administrative claims codes for these
treatments appearing within 1 week before, to 3 months after the date of
diagnosis.

Socioeconomic Data
Socioeconomic

information

included

education

level

and

median

household income. These were obtained from the 2000 US Census using the
patients’ residential street address. Census tract level data were used to
characterize the socioeconomic profile of each patient’s neighborhood of
residence.

Statistical Analysis
Patients were assigned into 4 distinct groups: patients with good PS who
received

chemotherapy;

patients with

good PS

who

did not

receive

chemotherapy; patients with poor PS who received chemotherapy; and patients
with poor PS who did not receive chemotherapy. Systematic unadjusted
differences between patients receiving chemotherapy and those who did not
receive chemotherapy, within the good PS and poor PS groups (patients in the
first two groups and patients in the latter two groups) were examined, using 2-
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sample Student t test (or Wilcoxon rank sum tests) and chi-square tests,
depending on the nature of the characteristic.
For survival analyses, conventional two-stage instrumental variable
methods may produce biased estimates in nonlinear models, and two-stage least
squares regression fails to account for time to death and disregards censoring.
Therefore, the two-stage residual inclusion (2SRI) method was used to account
for the endogeneity of chemotherapy receipt in estimating outcomes. Terza et al
(J. V. Terza et al. 2008). showed that 2SRI estimation is consistent across a
variety of nonlinear models, including survival models. In the first stage, logistic
equations were used to evaluate the factors associated with receipt (or nonreceipt) of chemotherapy (Y). Two distinct models were used for the good PS
and the poor PS groups, as described in chapter 3:

and

P(Yg=1|X) = exp(Z)/[1+exp(Z)]

for: PS=good

P(Yp=1|X) = exp(Z)/[1+exp(Z)]

for: PS=poor

where Z = β0 +X1β1 + X2β2 + X3β3 + X4β4 + X5β5 + e with each patient having
demographic covariates (X1), clinical characteristics (X2), socioeconomic
characteristics (X3), access to treatment (X4), and year of diagnosis (X5). The
residuals were calculated by subtracting the predicted likelihood of receiving
chemotherapy from the actual value of the treatment received. Two variables,
vehicle ownership and the year of diagnosis dummy variable (before/after 2003),
were identified as instrumental variables in these equations. The first stage
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residuals were included as additional covariates in the second stage, Cox
proportional hazards equations, along with the endogenous treatment variables
and other relevant covariates.

Survival Analysis
The objective of the survival analysis was to compare survival for patients,
stratified by PS and receipt of chemotherapy. Patients were initially grouped by
good vs. poor PS. After stratifying patients by chemotherapy receipt, Kaplan
Meier survival curves were created. The Kaplan-Meier estimator KM(t) describes
the probability that the time-to-death T exceeds any given value t. It is plotted as
a function of t over the range of times of interest and is a decreasing curve with
value 1 at time of diagnosis and other values given by:
KM(t) = π (1 - rsi),
i :si<t

where {s1, s2, …} are the observed death times and rs is the estimated hazard or
risk of death at time s, among all patients at risk of death at time s.
Cox proportional hazards regression analysis was used to evaluate the
impact of chemotherapy use by PS group, after adjusting for other relevant
clinical and socio-demographic characteristics and for the possible endogeneity
of chemotherapy using residuals from the first-stage logit equations. The Cox
regression is the most common regression approach used in time-to-event
problems, and describes the dependence of risk at any time t on the covariates in
the model (D. R. Cox 1972). It is semi-parametric in that no assumptions are
made about how the hazard rates vary with time; however, the hazards for
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different covariate values are assumed to be proportional with a ratio that is
constant over time. Two multivariate Cox regressions were fit to evaluate survival
given the patient’s PS:

and

^
hg(t|X) = h(t)exp(Xeβe + Xoβo + Xuβu) +e2SRI

for: PS=good

^ β ) +e2SRI
hp(t|X) = h(t)exp(Xeβe + Xoβo + X
u u

for: PS=poor

where Xe is the endogenous regressor (receipt or non-receipt of chemotherapy)
and Xo is a vector of observable exogenous covariates. In the 2 equations above,
^ is the residual from the first-stage model.
e2SRI is the regression error term and X
u
The first model estimated survival among patients with good PS (where
non-receipt of chemotherapy was considered under use) while the second model
estimated survival among patients with poor PS (where receipt of chemotherapy
was considered over use). Both models controlled for the receipt of initial surgery
and radiation therapy, patient age and AJCC stage at time of diagnosis, gender,
race, comorbidities, as well as the college graduation rate and median household
income in their neighborhood.
SAS statistical software (version 9.1.3; SAS Institute Inc, Cary, NC) was
used for all analyses. P < .05 was considered to be statistically significant.
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4.3 Results
Cohort Characteristics
A total of 406 patients met the criteria for study eligibility. Table 11 shows
the patient characteristics by PS. The mean age of the cohort was 66.9 years
(standard deviation [SD], 8.9 years) for patients with good PS, compared with
69.2 years (SD, 8.4) for those with poor PS. Just under half (42%) of good PS
patients were female versus 36% of poor PS patients, whereas the racial
distribution for good PS patients was 71% white, 27% black, and 2% of other
races, compared with 63% white, 34% black, and 3% other races for poor PS
patients. The AJCC staging distribution was as follows: for good PS, 11% of
patients were diagnosed with stage II disease, 43% were diagnosed with stage
IIII disease, and 46% were diagnosed with stage IV disease; for poor PS, 11% of
patients were diagnosed in stage II, 31% in stage III, and 58% in stage IV. The
average Charlson comorbidity index across the sample was 1.1 (SD, 1.4) for
good PS patients and 2.1 (SD, 2.1) for poor PS patients. Of all patients with good
PS, 63.4% died by the end of the study period and the mean survival was 20.2
months (SD, 21.4). Poor PS patients experienced significantly poorer survival
with 84.9% dying by the end of the study period and a mean survival of 10.5
months (SD, 16.1).
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Table 11. Overall Sample Characteristics and Survival, Lung Cancer Patients
with Stages II-IV, by Performance Status (PS) (n = 406)
Demographic Characteristics
Average age at diagnosis (SD)
Gender (%)
Female
Male
Race (%)
Black
White
Other
Clinical Characteristics
AJCC stage (%)
II
III
IV
Average Charlson comorbidity index (SD)
Socioeconomic Characteristics
Pct with college degree (SD)
Median household income in $1000s (SD)
Treatment(s) Received
No treatment (%)
Surgery only (%)
Radiation therapy only (%)
Chemotherapy only (%)
Surgery + radiation therapy (%)
Surgery + chemotherapy (%)
Radiation + chemotherapy (%)
Surgery + radiation + chemotherapy (%)
Survival
Mean survival time in months (SD)
Died by end of study period (%)

Good PS
N = 320
66.9 (8.9)

Poor PS
N = 86
69.2 (8.4)

42
58

36
64

27
71
2

34
63
3

11
43
46
1.1 (1.4)

11
31
58
2.1 (2.1)

6.9 (5.8)
49.7(21.7)

6.8 (5.1)
47.1(22.8)

8
1
10
15
1
6
50
9

28
1
31
11
0
0
27
2

20.2(21.4)
63.4

10.5(16.1)
84.9
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Chemotherapy Receipt by Performance Status
Table 12 reports the unadjusted differences in cohort characteristics
between patients receiving chemotherapy and those not receiving it, across 2
groups: patients with good PS and patients with poor PS. Among patients with
good

PS,

there

were

significant

differences

between

those

receiving

chemotherapy and those not receiving it by age at diagnosis, and the patient’s
Charlson comorbidity index. Among patients with poor PS, there were significant
differences between those receiving chemotherapy and those not receiving it by
age and median household income in the patient’s neighborhood. Among the
good PS group, patients who received chemotherapy had significantly greater
survival; the mean survival time was 21.7 months (SD, 20.6) for patients who
received chemotherapy versus 15.6 months (SD, 23.0) for those who did not,
while 61.7% of patients in this group who received chemotherapy died by the end
of the study period compared with 68.8% of those without chemotherapy.
Similarly, significant survival differences were recorded among the poor PS
group; patients with chemotherapy had a mean survival time of 13.6 months (SD,
19.1) compared with 7.9 months (SD, 12.8) for those without chemotherapy, and
84.6% of those receiving chemotherapy in this group died by the end of the study
period compared with 85.1% of those not receiving chemotherapy.
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Table 12. Sample Characteristics and Survival, by Performance Status (PS) and
Choice of Chemotherapy Receipt or Non-Receipt, for Lung Cancer Stages II-IV
(n = 406)
Good PS1 (n = 320)

Demographic Characteristics
Average age at diagnosis (SD)
Gender (%)
Female
Male
Race (%)
Black
White
Other
Clinical Characteristics
AJCC stage (%)
II
III
IV
Average Charlson comorbidity index (SD)
Socioeconomic Characteristics
Pct with college degree (SD)
Median household income in $1000s (SD)
Treatment(s) Received
No treatment (%)
Surgery only (%)
Radiation therapy only (%)
Chemotherapy only (%)
Surgery + radiation therapy (%)
Surgery + chemotherapy (%)
Radiation + chemotherapy (%)
Surgery + radiation + chemotherapy (%)
Survival
Mean survival time in months (SD)
Died by end of study period (%)

1

Poor PS2 (n = 86)

Chemo
(n = 243)

No Chemo
(n = 77)

Chemo
(n = 39)

No Chemo
(n = 47)

65.5 (8.5)3

71.4 (8.9)3

66.9 (9.0)4

71.1 (7.5)4

41
59

47
53

36
64

36
64

26
72
2

30
66
4

31
69
0

36
58
6

11
44
45
1.0 (1.4)3

12
42
48
1.4 (1.5)3

15
23
62
1.9 (2.0)

6
39
55
2.3 (2.3)

7.1 (6.0)
50.4(22.2)

6.1 (4.9)
47.6(19.8)

6.7 (5.9)
52.4(27.8)4

6.9 (4.4)
42.7(16.6)4

17
8
62
13

42
5
52
1
-

31
64
5

45
2
53
-

21.7(20.6)
61.7

15.6(23.0)
68.8

13.6(19.1)
84.6

7.9(12.8)
85.1

Good PS: ECOG 0-2
Poor PS: ECOG >2
3
Among patients with good PS, significant difference by chemotherapy receipt/non-receipt, at 5%
level
4
Among patients with poor PS, significant difference by chemotherapy receipt/non-receipt, at 5%
level
2
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Survival
To better understand the factors associated with improved survival,
univariate

and

multivariate

analyses

were

performed

using

patient

characteristics. The 2SRI analysis found that the residual from the first equation,
explaining factors associated with chemotherapy receipt, was not a significant
regressor in the second equation (survival model). Since the receipt of
chemotherapy was not found to be endogenous in the good PS two-stage model,
these preliminary findings are shown in the appendix, but excluded from final
results.
Overall

median

survival

was

longer

for

patients

who

received

chemotherapy in both the good and poor PS groups. Survival for patients who
received chemotherapy, regardless of PS, was superior to that of patients who
did not receive chemotherapy (Figure 1).
Table 13 lists the adjusted hazard ratios for the good PS group. The
sample is stratified by receipt of chemotherapy. Among patients with good PS,
the multivariate Cox regression analysis found that stage IV diagnosis (hazard
ratio [HR], 2.19) was significantly associated with a higher risk of dying, whereas
the receipt of chemotherapy (HR, 0.64), surgery (HR, 0.33), and female gender
(HR, 0.66) were all significantly associated with a lower risk of dying. The
residual from the first-stage equation was not significantly associated with the
dependent variable and was dropped from this table, but included in the
appendix. This suggested that there was no evidence of endogeneity for
chemotherapy in the good PS model.
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Alternative models that considered patients with PS=2 under the poor PS
group are presented in Appendix B. The major difference compared with the
baseline models is that chemotherapy was not significantly associated with a
lower risk of death for patients with good PS, when PS 2 patients are excluded
from this group.
Among patients with poor PS (table 14), the multivariate Cox regression
found that stage IV diagnosis (HR, 1.90) was associated with a higher risk of
dying, whereas the receipt of chemotherapy (HR, 0.04) was associated with a
lower risk of dying. Female gender (HR, 0.61) and living in a neighborhood with a
higher rate of college graduates (HR, 0.93) were associated with a lower risk of
dying. However, these associations were not significant at P < 0.05. There is also
evidence of an association between the residual from the first-stage equation and
the risk of dying (P = 0.06), suggesting that unobservable disturbances from the
first stage equation are associated with the dependent variable in the poor PS
Cox model.

69
Figure 1. Kaplan-Meier Curves by Chemotherapy Receipt for Patients with Good
Performance Status (PS)1 (A; N = 320) and Poor PS2 (B; N = 86)
A

B

1
2

Good PS: ECOG 0-2
Poor PS: ECOG >2
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Table 13. Multivariate Cox Proportional Hazards Model of Survival for Good
Performance Status (PS) Patients Diagnosed With Stage II-IV Lung Cancer
between 2000 and 2007 (N = 320)
Performance Status = Good1
Treatment Received
Chemotherapy
Surgery
Radiation
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Stage IV at diagnosis
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Model Characteristics
Likelihood ratio, χ2(10)
Probability > χ2

1

Good PS: ECOG 0-2

Parameter

Hazard Ratio

-0.45
-1.12
0.18

0.64
0.33
1.20

0.01
<.01
0.30

0.01
-0.41
0.29

1.01
0.66
1.34

0.20
<.01
0.12

0.78
0.02

2.19
1.02

<.01
0.75

0.01
-0.01

1.01
0.99

0.56
0.07

94.0
0.00

P Value
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Table 14. Multivariate Cox Proportional Hazards Model of Survival for Poor
Performance Status (PS) Patients Diagnosed With Stage II-IV Lung Cancer
between 2000 and 2007 (N = 86)
Performance Status = Poor1
Treatment Received
Chemotherapy
Surgery
Radiation
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Stage IV at diagnosis
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
First Stage Residual
Model Characteristics
Likelihood ratio, χ2(10)
Probability > χ2

1

Poor PS: ECOG >2

Parameter

Hazard Ratio

-3.20
-15.33
0.29

0.04
0.00
1.34

0.03
0.98
0.30

-0.04
-0.50
-0.32

0.96
0.61
0.73

0.09
0.06
0.33

0.64
0.08

1.90
1.08

0.02
0.14

-0.08
0.02
1.20

0.93
1.02
3.31

0.07
0.16
0.06

37.4
0.00

P Value
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4.4 Discussion
To my knowledge, this is the first study that examines the impact of
guideline recommended (and non-recommended) chemotherapy on survival of
lung cancer patients in a large cohort of managed care enrollees. There are
several findings to note from this study. First, all else equal, insured patients with
good PS who receive chemotherapy have significantly higher survival compared
with those with no chemotherapy. Second, similar patients with poor PS who
receive chemotherapy also have significantly higher survival compared with
those who do not receive chemotherapy. The two-stage model used to explain
this relationship suggests that other unobservable factors associated with the
receipt of chemotherapy in poor PS patients may have a positive impact on
survival. Further, by considering the alternative models that used the pre-2009
guidelines

in

defining

chemotherapy

appropriateness,

it

seems

that

chemotherapy may be especially beneficial for PS 2 patients. This finding
explains why the guidelines were revised to recommend chemotherapy for this
group of patients.
These conclusions should be interpreted in the light of several important
limitations. First, these findings are based on a cohort of insured cancer patients,
and survival rates as well as adherence rates may differ among an uninsured
population. Similarly, models were developed on a sample of patients receiving
their care from one delivery system located in a large urban area. Therefore, care
should be taken when generalizing findings to other delivery settings and locales.

73
Furthermore, models may exclude important factors associated with survival
including variations across health systems and geographical regions.
Second, some patients who were prescribed chemotherapy but did not
live long enough to receive treatment would be counted as having not received
chemotherapy. If survival after diagnosis predicts chemotherapy use, this could
bias survival in favor of those who received chemotherapy.
Finally, it is not known whether chemotherapy was given with good intent
in lieu of hospice for palliative reasons to those with poor PS, and if there was
any subsequent impact on symptom burden or hospitalizations for side effects.
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CHAPTER 5. CONCLUSION
Performance status is widely recognized as a predictor for treatment
appropriateness and reducing chemotherapy to patients with poor PS has been
recommended as one way to increase health care quality and reduce costs (T. J.
Smith, B. E. Hillner 2011). This is the first study to use observational data to
estimate PS for lung, or any other, cancer patients. Despite good predictability of
PS using this model, a predicted version will always be second-best to having the
actual PS data. Tumor registries should include PS as a required field in order to
assess quality of care.
Using the first large cohort of patients with lung cancer for whom PS is
known, this study found the overall adherence to evidence-based guidelines for
chemotherapy treatment to be 71%. Among those whose care was nonconcordant with guideline recommendations, 19% did not receive chemotherapy
when it was indicated and 10% received chemotherapy when it was not
recommended. This study recorded a higher adherence rate than previous lung
cancer studies that used population-based Medicare data and did not control for
PS (P. B. Bach et al. 1999;C. C. Earle et al. 2000;T. J. Smith et al. 1995;A. L.
Potosky et al. 2004) and found that older patients are less likely to use
chemotherapy, regardless of their PS.
The higher the median household income in the patient’s neighborhood of
residence the more likely they are to be out of compliance in both directions, both
“overusing” and “underusing” chemotherapy. Unlike other studies that analyzed
Medicare claims data, this study considered a rarely studied managed care
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cohort that included younger patients as well as older ones, although the median
age of 67 was close to the US median age at diagnosis of 71 (National Cancer
Institute 2010). Another notable difference of this study is that it found no racial
differences in the receipt of chemotherapy (either underuse or overuse), which
suggests that disparities may be attributable to other factors. Among the
urban/suburban population studied here, this study did not find travel distance to
be associated with recommended chemotherapy treatment. Instead, it was found
that if fewer households in a patient’s neighborhood had access to a car, this
travel barrier was associated with underuse of chemotherapy relative to guideline
recommendations. This finding suggests that patients without access to a car
may have difficulty reaching a clinic, even when there is a clinic a relatively short
distance from their home. This suggests a helpful question to ask on intake
screening: “Will you have difficulty getting to your next appointment?”
Finally, this is the first study that examines the impact of guideline
recommended chemotherapy on survival of lung cancer patients in a large cohort
of managed care enrollees. The study found that regardless of PS, patients who
received chemotherapy had significantly higher survival compared with those
who did not receive chemotherapy, although the model suggests that other
unobservable factors associated with the receipt of chemotherapy in poor PS
patients may have a positive impact on survival.
This study is not without its limitations. First, subjectivity is present in the
assignment of PS. It is documented that PS scales are subjective in nature, and
when estimated by physicians they are known to be prone to error, usually being
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overestimated. Second, the study relies on a relatively small sample that is
specific to one health care delivery system, located in a large urban area. The
findings of this study may not be generalized, especially to non-urban
populations. Third, the models in this study may exclude relevant measures,
including provider characteristics and variations across health systems and
geographic areas. Also, these findings are based on an insured cohort of lung
cancer patients, and may be different among the uninsured. Finally, this study
was not intended to assess specific chemotherapy regimens. Therefore it is not
known whether chemotherapy was given with good intent in lieu of hospice for
palliative reasons to those with poor PS.
Given the limitations of the current study, several ideas for future research
emerge. First, the analysis could be expanded to include multiple health systems,
with a larger cohort of patients and geographic variations. The advantage of
having a larger, more diverse cohort to study will allow for the examination of
more factors, including provider characteristics and health system variations, and
allow for the study of treatment costs. A priority in the study of costs would be to
define a treatment episode for lung cancer patients and measure per episode
costs. Once the treatment episode is defined, cost effectiveness analysis could
be performed using survival and cost resulting from lung cancer treatment.
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APPENDIX
Appendix A. Factors Associated with Non-Receipt of Chemotherapy among
Patients with Good Performance Status (PS) (N = 276) and Receipt of
Chemotherapy among Patients with Poor PS (N = 130)
Performance Status = Good1
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Access to Treatment
Pct without vehicle
Distance to chemo facility
Guidelines
Year of diagnosis < 2003
Model Performance
Pseudo-R2
C-statistic
Performance Status = Poor2
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Access to Treatment
Pct without vehicle
Distance to chemo facility
Guidelines
Year of diagnosis ≥ 2003
Model Performance
Pseudo-R2
C-statistic

1
2

Good PS: ECOG 0-2
Poor PS: ECOG>2

Odds of Under Use (95% CI)

P Value

1.10 (1.06-1.14)
1.37 (0.74-2.54)
0.71 (0.31-1.64)

<0.01
0.31
0.43

1.20 (0.97-1.49)

0.10

0.96 (0.88-1.04)
1.02 (1.00-1.05)

0.35
0.09

5.12(0.55-47.79)
1.00 (0.98-1.03)

0.15
0.56

2.29 (1.22-4.32)

0.01

Odds of Over Use (95% CI)

0.14
0.75
P Value

0.93 (0.89-0.98)
0.78 (0.35-1.74)
0.94 (0.38-2.35)

0.01
0.54
0.90

0.99 (0.81-1.20)

0.91

1.00 (0.90-1.10)
1.03 (1.00-1.06)

0.91
0.09

0.91(0.11-7.56)
0.98(0.93-1.03)

0.93
0.40

2.59(1.12-6.00)

0.03
0.13
0.71
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Appendix B. Two-Stage Residual Inclusion Method: Multivariate Cox Proportional
Hazards Models with Residuals from Chemotherapy Receipt Logit Regression,
(N = 320)
Performance Status = Good1
Treatment Received
Chemotherapy
Surgery
Radiation
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Stage IV at diagnosis
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Residual
Model Characteristics
Likelihood ratio, χ2(10)
Probability > χ2

1

Good PS: ECOG 0-2

Parameter

Hazard Ratio

-1.54
-1.12
0.19

0.21
0.33
1.21

0.15
<.01
0.29

-0.00
-0.48
0.38

1.00
0.62
1.46

0.91
<.01
0.06

0.79
0.02

2.20
1.00

<.01
0.97

-0.00
-0.02
0.47

1.02
0.99
1.60

0.38
0.04
0.30

95.0
0.00

P Value
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Appendix C. Alternative Models with Pre-2009 Definition of Performance Status
(PS): Multivariate Cox Proportional Hazards Model of Survival for Patients
Diagnosed With Stage II-IV Lung Cancer between 2000 and 2007

1
2

Performance Status = Good1
Treatment Received
Chemotherapy
Surgery
Radiation
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Stage IV at diagnosis
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Model Characteristics
Likelihood ratio, χ2(10)
Probability > χ2

Parameter

Hazard Ratio

-0.34
-1.15
0.21

0.71
0.32
1.24

0.09
<.01
0.28

0.01
-0.39
0.49

1.01
0.67
1.63

0.34
0.02
0.02

0.74
0.09

2.09
1.09

<.01
0.18

0.02
-0.01

1.02
0.99

0.40
0.03

78.0
0.00

N=276

Performance Status = Poor2
Treatment Received
Chemotherapy
Surgery
Radiation
Patient Demographics
Age at diagnosis (years)
Gender = female
Race = white
Clinical Characteristics
Stage IV at diagnosis
Charlson comorbidity index
Socioeconomic Characteristics
College degree
Median income ($1000s)
Residual
Model Characteristics
Likelihood ratio, χ2(10)
Probability > χ2

Parameter

Hazard Ratio

-2.84
-2.48
0.18

0.06
0.08
1.20

0.04
0.02
0.40

-0.01
-0.55
-0.27

0.98
0.58
0.76

0.38
0.01
0.29

0.60
0.01

1.83
1.01

0.01
0.83

-0.02
0.01
0.96

0.98
1.01
2.62

0.50
0.22
0.10

41.3
0.00

N=130

Good PS: ECOG 0-1
Poor PS: ECOG >1

P Value

P Value
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Evidence-based guidelines recommend chemotherapy for medically fit
patients with stage II-IV non-small cell lung cancer (NSCLC). Adherence to
chemotherapy guidelines has rarely been studied among large populations,
mainly because performance status (PS), a key component in assessing
chemotherapy appropriateness, is missing from claims-based datasets. Among a
large cohort of patients with known PS, this dissertation describes chemotherapy
use relative to guideline recommendations and identifies patient factors and
outcomes associated with guideline concordant use. Among these patients 29%
do not receive guideline recommended chemotherapy treatment, missing
opportunities for cure or receiving chemotherapy with more risk of harm than
benefit, thereby likely foregoing beneficial palliation. Care concordant with
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guidelines is influenced by age, and economic considerations, such as income,
and transportation barriers. Guideline adherent use of chemotherapy reduced
risk of dying. Overuse of chemotherapy also reduced risk of dying. Among poor
PS patients, stage IV diagnosis was also associated with survival. Chemotherapy
has positive effects on survival for both good and poor PS patients. In the poor
PS group, the relationship between chemotherapy and survival is affected by
other unobservable factors.
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